JLK, Obtains Patent for Prostate Cancer Diagnosis AI Solution... Proving 'Unrivaled AI Diagnostic Technology'

JLKEI, the first medical AI listed company (CEO Dongmin Kim), announced on the 9th that its prostate cancer artificial intelligence solution, which successfully obtained the U.S. Food and Drug Administration (FDA) 510(k) approval, has also secured a domestic technology patent.

According to the Korean Intellectual Property Office, the "AI-based prostate cancer pathology image report system" filed by JLKEI in 2020 was finally granted a technology patent earlier this month.

With this decision, JLKEI has once again proven the technological excellence of "MEDIHUB Prostate," which comprehensively analyzes prostate MR images and provides all necessary data for prostate cancer diagnosis, including AI-based PIRADS diagnosis and PSA (Prostate-Specific Antigen) density diagnosis.

According to the 2023 report from the Global Cancer Observatory, prostate cancer is one of the most common cancers among men in OECD countries and is ranked as the number one cancer diagnosis among men in the United States.

JLKEI's "MEDIHUB Prostate" has already completed global technology validation, including FDA approval in the U.S. last month. It is particularly noted for being developed through clinical trials at Seoul Asan Medical Center in Korea and the University of Missouri in the U.S., taking into account diverse racial characteristics.

In the U.S., men over 50 have a 40% lifetime risk of experiencing latent prostate cancer, with more than 288,300 new prostate cancer diagnoses annually and approximately 34,700 deaths from prostate cancer each year. The prostate cancer market is expected to reach $21.5 billion (approximately 30 trillion KRW) by 2030, with an annual growth rate projected at 12.4%.

JLKEI CEO Dongmin Kim emphasized, "With the patent decision for MEDIHUB Prostate and FDA approval in the U.S., JLKEI's medical AI technology capabilities have been recognized both domestically and internationally. Taking this as an opportunity, we will aggressively pursue FDA applications and market entry for five solutions scheduled this year to achieve tangible results."